Abortion Pill

Abortion groups work to sneak abortion pill into pharmacies worldwide under guise of treating other conditions

abortion pill, distributing abortion pills

Gynuity Health Projects—a pro-abortion research group working to increase access to the abortion pill—wants the pill used to treat conditions unrelated to abortion. Getting the abortion pill approved to treat medical conditions means it will be easier to get the pill into countries where abortion is illegal, and where the abortion pill is banned.

Reproductive Health Supplies Coalition (RHSC) revealed this strategy in a webinar, which includes a presentation and video. Gynuity received a $108k grant from the RHSC’s Innovation Fund to conduct “a landscape analysis that will identify market gaps, bottlenecks, and potential country-level opportunities to register and commercialize mifepristone for its other indications.”

Formed in 2004, RHSC took off in 2012 when it became involved in the Gates-funded Family Planning 2020 initiative. The coalition includes the Bill and Melinda Gates Foundation, the Bixby Center for Global Reproductive Health, the David and Lucile Packard Foundation, DKT International, GenBioPro, the Guttmacher Institute, Ibis Reproductive Health, Planned Parenthood, and the Population Council. Its current executive committee includes representatives from the Population Council, the Bill and Melinda Gates Foundation, Planned Parenthood Federation of America, and the United Nations Population Fund.

Jennifer Blum, Gynuity’s VP for Programs and Strategic Initiatives, and former Program Officer for the Packard Foundation—a  major early investor in the manufacturer of the abortion pill—said in the webinar that registering the abortion pill to treat conditions unrelated to abortion is to “bypass hurdles.” Blum noted, “The number of countries with mifepristone [the abortion pill] is increasing but in places with restrictive abortion laws, access remains challenging.”

In addition to the “known” indications such as “incomplete abortion, missed abortion, second-trimester abortion, [and intra-uterine fetal death],” the webinar notes that there is interest in labeling the drug “specifically for menstrual regulation” in places like West Africa and South America.

Image: Gynuity webinar Mifepristone indications slide

Gynuity webinar Mifepristone indications slide.

Gynuity Senior Program Associate Laura Frye introduced a “tangible briefing document,” summarizing a list of additional indications that would get mifepristone into pharmacies around the world. The document states (emphasis added):

One strategy to increase availability and market sustainability of mifepristone is to register it for additional indications. Several of these “uncontroversial” indications are legal in most jurisdictions and could provide an entry point for the medication to be listed on national drug registries, stocked in hospitals and other health care facilities, and integrated into health care systems.

In countries where there are highly restricted legal indications for abortion and/or where opposition to abortion on request impacts drug registration regulatory processes, focusing on other indications may eliminate some hurdles to product registration. Additionally, in the face of constrained health care budgets, medications that address multiple indications may be more appealing for purchase by health systems.

The group expressed the importance of selecting medical conditions that would require the same dosages needed for effective chemical abortions as “a segway to registering the same 200mg tablets” for a chemical abortion. Blum then claimed other abortion pill stakeholders have an interest in exploring this expansion option but have little time or money to develop or implement a strategy. Those stakeholders include:

  • PSI, which works to “strengthen access to medication abortion through direct product distribution and market facilitation… launch[ing] misoprostol and mifepristone-misoprostol combination-pack brands in nearly 20 countries and support[ing] already existing commercial brands in more than 15 countries”
  • Marie Stopes International, which markets an abortion pill “Combipack” called Mariprist
  • Danco Laboratories, the US manufacturer of the abortion pill (Mifeprex)
  • Linepharma, a company that markets a “Combi-Pack” in Australia (MS 2-Step™) and Canada (Mifegymiso®)
  • Naari, which markets the abortion pill under multiple names in several countries
  • International Planned Parenthood Federation, which has created a global chemical abortion database
  • DKT International, which sells abortion pills globally
  • Concept Foundation, whose donors and partners include the Gates and Packard Foundations, and which has developed a “combipack” called Medabon “in partnership with the World Health Organization and Sun Pharma”

Ayisha Diop, a Program Associate for Gynuity, identified six countries where abortion is either restricted or no abortion pill products are registered: Burkina Faso, Colombia, Kenya, Latvia, Pakistan, and Senegal. She stressed a need to “provide a legal cover… so that pharmacists and providers would feel safe using the medication.” Diop added that the legal indication should be “non-abortion related so that it wouldn’t cause controversy.”

The deception and lies the abortion industry is using to expand access to the dangerous abortion pill will put more women at risk and will kill more preborn children. Increased use of the abortion pill does not benefit women but instead lines the pockets of the abortion industry and its investors.

Like” Live Action News on Facebook for more pro-life news and commentary!

What is Live Action News?

Live Action News is pro-life news and commentary from a pro-life perspective. Learn More

Contact editor@liveaction.org for questions, corrections, or if you are seeking permission to reprint any Live Action News content.

GUEST ARTICLES: To submit a guest article to Live Action News, email editor@liveaction.org with an attached Word document of 800-1000 words. Please also attach any photos relevant to your submission if applicable. If your submission is accepted for publication, you will be notified within three weeks. Guest articles are not compensated. (See here for Open License Agreement.) Thank you for your interest in Live Action News!

To Top